Free Essay About Gilead Sciences Inc.

GILEAD SCIENCES INC 2

Gilead
Gilead Science Inc.  is a research-based biopharmaceutical company. It discovers, develops and sells different medicines all over the world. Main spheres of the company’s interest lie promoting medicines from human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions.

Here are main products of the company.

The company operates all over the world; it has more than 100 departments in different parts of the world. Gilead is a very powerful company that has a great impact on world health

GILEAD SCIENCES INC 3

industry. Its role is very important, because the latest researches and developments aimed to reduce the mortality from several diseases and prevent their spread.
One of the main area of Gilead’s focus is HIV/AIDS. Together with Jonson&Jonson (JNJ) they discovered and promoted Eviplera – an effective medicine that blocks the spread of the human immunodeficiency virus. It was approved in Europe in August 2011 and the same year in November - in the USA.
Sovaldi is another unique medicine. It helps people with hepatitis C. Nowadays it is seen like one of the world’s safe and secure way of the disease therapy. The only disadvantage of this medicine is its price. It coast $84,000 for a 12-week course. It is obvious, that most people are not able to pay such a price. That’s why the company decided to make the medicine more accessible. Gilead has signed an agreement with seven companies in India to produce Sovaldi at a lower price. This cheaper version will cost $900 for a 12-week couse and will be sold in 91 countries such as Kenya, Mozambique, Myanmar and India. The amount of people living with the hepatitis C in these countries is more than 100 million people, representing 54% of the total global infected population. From this example, we see how important the Gilead’s activity is for people and that the company has not only profit orientation, but also serves the public good.
Oncology is also very interested for Gilead. Its first cancer drug called Zidelig. Zydelig is among a new class of drugs known as PI3k inhibitors. It was approved in the U.S. to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma. In the U.S., analysts are reporting that Gilead has priced Zydelig lower than its top competitor, Johnson & Johnson's Imbruvica (ibrutinib)--$7,200 per month vs. $8,200. When added to Rituxan or another cancer treatment, however, the cost of Gilead's therapy could rise to $12,000, they estimate.

GILEAD SCIENCES INC 4

Gilead look forward to create new medicine from serious diseases. With this purpose it has signed a definitive agreement with Phenex Pharmaceuticals AG, a privately-held biotechnology company. Under this agreement Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). Under the terms of the agreement, Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth up to $470 million (Fransico, 2014).
GILEAD SCIENCES INC 5

References

O’Brien, P. (2015, January 6). Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals’ Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases. Business Wire, pp. 21-23.
FRANCISCO. ( 2014, December 8). the 56th American Society of Hematology Annual Meeting. Business Wire, pp. 3-5.
Gilead’s investigational cancer agents from www.clinicaltrials.gov.